...
首页> 外文期刊>Scientific reports. >Statin therapy and recurrent venous thromboembolism in the elderly: a prospective cohort study
【24h】

Statin therapy and recurrent venous thromboembolism in the elderly: a prospective cohort study

机译:老年人治疗和复发性静脉血栓栓塞 - 一种潜在的队列研究

获取原文

摘要

Previous studies reported lower rates of recurrent venous thromboembolism (rVTE) among statin users, but this association could be influenced by concurrent anticoagulation and confounding by statin indication. This study aimed to confirm the beneficial association between statins and rVTE, stratified according to periods with and without anticoagulation, and additionally employ propensity score weighted approach to reduce risk of confounding by indication. The setting was a prospective multicentre cohort study and the outcome was time to first rVTE in statin vs. non-statin users. 980 participants with acute VTE were enrolled (mean age 75.0 years, 47% women), with median follow-up of 2.5 years. Of 241 (24.3%) statin users, 21 (8.7%) suffered rVTE vs. 99 (13.4%) among 739 non-users. The overall adjusted sub-hazard ratio (aSHR) for rVTE comparing statin users to non-users was 0.72 (95%CI 0.44 to 1.19, p?=?0.20). This association was only apparent during periods without anticoagulation (aSHR 0.50, 95%CI 0.27 to 0.92, p?=?0.03; vs. with anticoagulation: aSHR 1.34, 95%CI 0.54 to 3.35, p?=?0.53). Using propensity scores, the rVTE risk during periods without anticoagulation fell further (aSHR 0.20, 95%CI 0.08 to 0.49, p??0.001). In conclusion, statin use is associated with a more pronounced risk reduction for rVTE than previously estimated, but only during periods without anticoagulation.
机译:以前的研究报告了他汀类药物中反复性静脉血栓栓塞(RVTE)的率较低,但这种关联可能受到同时抗凝和肠毒素迹象的影响。本研究旨在确认他汀类药物和RVTE之间的有益关联,根据有抗凝血和无抗凝的周期分层,并且另外采用倾向评分加权方法,以降低通过指示减少混淆的风险。该环境是一个预期的多期式队列研究,结果是在他汀类动物与非他汀类药物中的第一个RVTE的时间。 980名急性VTE的参与者注册(平均年龄75.0岁,47%的妇女),中位随访2.5岁。 241例(24.3%)他汀类药物,21例(8.7%)在739名非用户之间遭受了RVTE与99(13.4%)。用于RVTE的整体调整后的子危险比(ASHR)将他汀类药物与非用户进行比较为0.72(95%CI 0.44至1.19,P?= 0.20)。这种关联在没有抗凝血的期间(ASHR 0.50,95%CI 0.27至0.92,p≤0.03;与抗凝:ASHR 1.34,95%CI 0.54至3.35)的时期仅明显。使用倾向分数,在没有抗凝血的期间内的RVTE风险进一步下降(ASHR 0.20,95%CI 0.08至0.49,P?<0.001)。总之,他汀类药物的使用与RVTE比以前估计的RVTE更明显的风险降低相关,但仅在没有抗凝血的期间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号